JNJ vs LQDA: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
JNJ is the larger of the two ($617.78B market cap): the incumbent the market prices for continued execution (20.07x forward earnings, beta 0.23). LQDA is the smaller challenger ($7.48B), cheaper on forward earnings (14.48x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
JNJ vs LQDA: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | JNJ | LQDA | What it tells you |
|---|---|---|---|
| Market cap | $617.78B | $7.48B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 20.07 | 14.48 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 29.77 | 494.76 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.23 | 0.55 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 83% of range | 90% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 7.27 | 68.38 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: LQDA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how JNJ and LQDA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and LQDA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and LQDA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Johnson & Johnson (JNJ) do?
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.
What does Liquidia Corporation (LQDA) do?
Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension. Its lead product, Yutrepia (treprostinil inhalation powder), is a dry-powder inhaled prostacyclin approved for pulmonary arterial hypertension (PAH) and for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Yutrepia received final FDA approval in May 2025 and launched commercially in June 2025. The company also runs a legacy generic-treprostinil business (Yuvanci/Treprostinil Injection) and is developing L606, an investigational sustained-release inhaled treprostinil dosed twice daily with a next-generation nebulizer, now in the pivotal Phase 3 Re-Spire study.
JNJ vs LQDA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
- LQDA drivers: Yutrepia commercial ramp; Swing to profitability.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For LQDA, liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately.
JNJ or LQDA: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; LQDA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and LQDA guides.
JNJ vs LQDA: the full fundamentals
JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.
LQDA. Liquidia trades at a large multiple of its trailing revenue, reflecting how much of the story is future Yutrepia growth toward the company's stated $1 billion 2027 revenue target rather than results already booked. The shares traded in roughly the low-to-high $70s in early-to-mid July 2026, well above levels from before the launch. Because revenue is concentrated in one product still early in its ramp, the valuation is sensitive to quarterly uptake data and to the outcome of the United Therapeutics patent litigation.
Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; LQDA shows q1 2026 revenue ~$133M (Yutrepia net sales ~$130M), revenue (ttm) ~$300M (Yutrepia launched June 2025), q1 2026 net income ~$53M (third straight profitable quarter), q1 2026 adjusted ebitda ~$71M.
The bottom line: JNJ vs LQDA
JNJ and LQDA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and LQDA exposure against your real portfolio. It is not an investment adviser.
Wondering how JNJ or LQDA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Johnson & Johnson with AI
Connect the broker you already use and ask Walnut's AI how JNJ fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between JNJ and LQDA?
+
Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Liquidia Corporation is a specialty pharmaceutical company focused on treating pulmonary hypertension. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is JNJ or LQDA the better stock?
+
Neither is universally better. JNJ is the larger incumbent; LQDA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, JNJ or LQDA?
+
On forward P/E (as of August 2026), JNJ trades at 20.07x and LQDA at 14.48x, so LQDA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both JNJ and LQDA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of JNJ vs LQDA?
+
JNJ: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. Drug pricing pressure, including US government negotiation of certain drug prices, can weigh on margins. The company also faces significant legal liability, most notably ongoing litigation related to talc-based products, which has created uncertainty and large potential settlements. MedTech competes in tough device markets and is exposed to hospital budgets and procedure volumes. Regulatory, clinical-trial, and product-safety risks are inherent to healthcare. Growth is steady rather than rapid, so J&J is valued as a defensive compounder rather than a high-growth name. LQDA: Liquidia is highly concentrated: the vast majority of revenue comes from a single drug, Yutrepia, in a single therapeutic area, so any slowdown in uptake, reimbursement pressure, or manufacturing or supply issue would hit results disproportionately. United Therapeutics has an ongoing patent-infringement lawsuit (centered on U.S. Patent No. 11,826,327, which expires in 2042) that went to trial in June 2025 with a decision awaited, and an adverse ruling in that or related patent matters could limit Liquidia's ability to keep approval for or commercialize Yutrepia. The company competes directly against United Therapeutics' larger, entrenched Tyvaso franchise. The stock also carries a premium valuation that assumes continued rapid growth toward the stated $1 billion 2027 target, so any disappointment on volumes, pricing, or litigation could produce sharp downside, and L606 approval is not guaranteed.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell JNJ or LQDA; figures are approximate and dated (as of August 2026). Verify current data before investing.